e-Article
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
Document Type
Article
Author
Carvajal, René; Tur, Carmen; Martínez-Gómez, Xavier; Bollo, Luca; Esperalba, Juliana; Rodriguez, Marta; Pappolla, Agustín; Cobo-Calvo, Alvaro; Carbonell, Pere; Borras-Bemejo, Blanca; Río, Jordi; Castilló, Joaquín; Braga, Nathane; Mongay-Ochoa, Neus; Rodrigo-Pendás, José Ángel; Vidal-Jordana, Ángela; Arrambide, Georgina; Rodríguez-Acevedo, Breogán; Zabalza, Ana; Midaglia, Luciana
Source
Subject
*VACCINE effectiveness
*CHICKENPOX
*MULTIPLE sclerosis
*MMR vaccines
*HERPES zoster vaccines
*CHICKENPOX vaccines
*
*
*
*
*
Language
ISSN
1352-4585
Abstract
Background: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. Objectives: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Methods: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Results: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3–78.3) versus 97.2% (95% CI: 85.5–99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. Conclusion: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization. [ABSTRACT FROM AUTHOR]